Vanda Pharmaceuticals Inc.

VNDANASDAQHealthcare● Active

$5.94

$-0.09(-1.49%)

Market Cap$357205238

P/E Ratio—

52W High$9.94

52W Low$4.14

Avg Volume1.4M

Open$6.11

Beta0.60

Overview

Stock ranking:Biotechnology·Healthcare·View All Market Cap Rankings →

Vanda Pharmaceuticals Inc. (VNDA) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · VNDA · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-4.05Earnings history

PE Ratio (TTM)—PE Ratio deep dive

Revenue (TTM)$217.8MFull revenue history

Dividend YieldNo DividendDividend history

Shares Outstanding58.9MShares outstanding history

Next EarningsJul 30, 2026Est.Earnings history

Explore Vanda Pharmaceuticals Inc. Data

Market Cap$357.2M

Analyst Forecast$14 · Buy

DividendsNo Dividend

Revenue$216.1M+8.72%

EarningsEPS $-3.74-1068.75%

PE Ratio—

Financial Snapshot

Full Financials

FY 2025Revenue$216.1M▲ +8.72% YoY

202320242025

FY 2025Net Income-$220.5M▼ 1066.53% YoY

202320242025

FY 2025EPS$-3.74▼ 1068.75% YoY

202320242025

TTM:Revenue: $217.8MNet Income: -$239.5MEPS: $-4.05View income statement →

Analyst Ratings & Price Target

Full Forecast

Buy19 analysts

Strong Buy

Buy

Hold

Sell

Strong Sell

12-Month Price Target

$7.50Low

$5.94Current

$14.25Avg Target139.90% upside

$21.00High

Total: 19 · Buy rate: 68.4%

The VNDA analyst consensus is Buy, based on ratings from 19 Wall Street analysts over the past 3 months. The average 12-month price target is $14.25, representing +139.90% upside from the current price of $5.94.

Competitors & Peers

#TickerCompanyPriceChangeMkt Cap

VNDA

Vanda Pharmaceuticals Inc.

$5.94-1.49%$357.2M #2

ACHV

Achieve Life Sciences, Inc.

$5.48+6.82%$562.6M #3

ALLO

Allogene Therapeutics, Inc.

$1.85-1.60%$451.2M #4

ARCT

Arcturus Therapeutics Holdings Inc.

$7.12-2.47%$202.4M #5

AVIR

Atea Pharmaceuticals, Inc.

$4.32+1.65%$345.7M #6

CAPR

Capricor Therapeutics, Inc.

$26.16-2.06%$1.2B

Stock Performance

Full History

1D-1.08%

1W-3.17%

1M-5.02%

3M-24.40%

YTD-32.37%

1Y+29.96%

5Y-68.20%

About Vanda Pharmaceuticals Inc.

CEOMihael H. Polymeropoulos

IPO DateApr 12, 2006

Employees368

CountryUS

Websitevandapharma.com

Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two …

Biotechnology HealthcareNASDAQUS

About Stock Overview & Key Data

Vanda Pharmaceuticals Inc. (VNDA) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Apr 12, 2006. As of the latest trading session, VNDA stock price is $5.94, with a market capitalization of $357.2M. The stock has returned +29.96% over the past 12 months and -32.37% year-to-date.

According to 19 Wall Street analysts, the consensus rating for Vanda Pharmaceuticals Inc. stock is Buy, with an average 12-month price target of $14.25. In fiscal year 2025, Vanda Pharmaceuticals Inc. reported revenue of $216.1M and net income of -$220.5M. For detailed data — including Vanda Pharmaceuticals Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Vanda Pharmaceuticals Inc. (VNDA) stock price is $5.94. The stock is traded on NASDAQ under the ticker symbol VNDA. The 52-week range is $4.14 – $9.94.

VNDA stock priceVNDA quote todaylive ticker

Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice